[3/22 Webinar] Unearthing the latent value of the seeds ~True strength and value illuminated by FRONTEO AI Drug Discovery BKM~
Many pharmaceutical companies are increasingly in-licensing their development pipelines from external partners.There are many drug discovery venture companies among the licensees, and at the same time, it is an opportunity for drug discovery venture companies. There is a need to show superiority.
On the other hand, it is also true that there are constraints in terms of funds, time, etc. in order to newly conduct "acquisition of additional data", "clarification of points of difference", and "further corroboration of MoA" in order to demonstrate superiority. .
FRONTEO has Drug Discovery AI and data scientists and bioscientists who operate it, and performs "non-biased" and "exhaustive" searches in a "short period of time" to discover new strengths of seeds and unearth added value. We are here to help.
In this webinar, we will introduce FRONTEO's Drug Discovery Best Known Method (DD-BKM) and propose a value-added improvement service that uncovers the latent value of seeds.
◆Theme: Unearthing the latent value of seeds ~True strength and value illuminated by FRONTEO AI Drug Discovery BKM~
Date: March 2023, 3 (Wednesday) 22:12-10:12
・Those who belong to venture capital
・Those who belong to a pharmaceutical company (research)
◆Participation conditions: Those who use the free address, those who are in the same industry as our company, and those whose affiliation is unknown are not allowed to apply.When accessing ZOOM on the day, please enter the name and email address you entered at the time of application in the ZOOM participation entry field.
Articles in the same category
[Online seminar held on 5/30] Practical techniques for legal due diligence for M&A
[5/31 15th Fraud Countermeasures Study Session] [Must-see for compliance personnel] Mass media response in the event of a crisis
[Online seminar held on 5/9] New framework and practical outlook for European foreign investment regulations - Explanation of the European Commission's new regulation proposal and the regulatory environment of major countries -
[Real seminar held on 4/18] “Crisis management proposed by a competition law/consumer law boutique firm” ~Risk management to avoid a “crisis”~
Exploring patient stratification biomarkers for IgA nephropathy using AI: Overcoming bias with AI
Searching for therapeutic targets for pancreatic cancer - I tried using paper search AI -
Parkinson's disease - Analyzing drug discovery targets using paper search AI
Economic Security Symposium co-hosted by FRONTEO x Moody's Analytics Japan on April 4th
Searching for new targets for sporadic ALS using AI: Become friends with AI
